Rapid-acting insulin is a type of insulin designed to mimic the body's natural insulin response to food, providing quick blood sugar control. It has a fast onset of action, typically within 15-30 minutes, peaks in about 30-90 minutes, and generally lasts for 3-5 hours. This makes it suitable for use at mealtime to cover the carbohydrate intake and manage the post-meal rise in blood glucose.
Rapid-acting insulins are genetically engineered human insulins that have been modified to absorb more quickly from the injection site into the bloodstream. Common examples include insulin aspart (Novolog) and insulin lispro (Humalog). They are essential in the management of both type 1 and type 2 diabetes, often used in conjunction with longer-acting insulins or oral medications. Given its rapid action, precise timing relative to meals is crucial for effectiveness and to minimize the risk of hypoglycemia (low blood sugar), which is a primary concern with all insulins.
Patients using rapid-acting insulin must receive personalized dosing instructions and training from a licensed healthcare professional, as dosages vary significantly based on individual metabolic needs, carbohydrate intake, and blood sugar levels. Administration is typically via subcutaneous injection, using syringes, pens, or insulin pumps.
Deep dive
Tap a section to expand.
Known interactions
Category rule: peptide × hormone
Note
Injectable peptides plus hormones can have overlapping or compounding effects that aren't always well characterized.
Track bloodwork with a provider; don't assume combinations are neutral.
Compound-pair rule
Caution
Combining a GLP-1 with rapid insulin increases hypoglycemia risk.
Reduce mealtime insulin at GLP-1 initiation; monitor glucose closely.
Compound-pair rule
Caution
Combining a GLP-1 with rapid insulin increases hypoglycemia risk.
Reduce mealtime insulin at GLP-1 initiation; monitor glucose closely.
Compound-pair rule
Caution
Combining a GLP-1 with rapid insulin increases hypoglycemia risk.
Reduce mealtime insulin at GLP-1 initiation; monitor glucose closely.
Compound-pair rule
Caution
Combining a GLP-1 with rapid insulin increases hypoglycemia risk.
Reduce mealtime insulin at GLP-1 initiation; monitor glucose closely.
Compound-pair rule
Caution
Combining a GLP-1 with rapid insulin increases hypoglycemia risk.
Reduce mealtime insulin at GLP-1 initiation; monitor glucose closely.
Compound-pair rule
Caution
Combining a GLP-1 with rapid insulin increases hypoglycemia risk.
Reduce mealtime insulin at GLP-1 initiation; monitor glucose closely.
Compound-pair rule
Caution
Combining a GLP-1 with rapid insulin increases hypoglycemia risk.
Reduce mealtime insulin at GLP-1 initiation; monitor glucose closely.
Compound-pair rule
Caution
Combining a GLP-1 with rapid insulin increases hypoglycemia risk.
Reduce mealtime insulin at GLP-1 initiation; monitor glucose closely.
Frequently asked
Sources referenced
["Cochrane Library", "DrugBank", "European Medicines Agency (EMA) - Summary of Product Characteristics (SmPC)", "Food and Drug Administration (FDA) - Label Information", "Mayo Clinic", "MedlinePlus (National Library of Medicine)", "National Institutes of Health (NIH) - Office of Dietary Supplements (ODS)"]
Stackwise compiles summaries from publicly available scientific and regulatory references. Always verify important decisions with a licensed clinician.
Related compounds
Others in the hormone category or studied for the same goals.